Argo Biopharma

Argo Biopharma is a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company utilizes its proprietary RADS™ (RNA molecules with superior Activity, Durability, and Safety) platform to create treatments for a wide range of indications, including cardiovascular diseases, metabolic conditions, viral hepatitis, CNS disorders, and rare diseases. Headquartered in Shanghai, China, with a global outlook, Argo Biopharma has established a robust pipeline of RNAi drug candidates. The company is actively advancing multiple assets into mid-stage clinical development and has formed significant strategic collaborations, most notably with Novartis, to accelerate the development and commercialization of its cardiovascular portfolio.